MUSK
Muscle, skeletal receptor tyrosine-protein kinase
Also known as: MUSK_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O15146
- Gene
- MUSK
- Ensembl
- ENSG00000030304
- Chromosome
- 9
- Canonical length
- 869 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a muscle-specific tyrosine kinase receptor. The encoded protein may play a role in clustering of the acetylcholine receptor in the postsynaptic neuromuscular junction. Mutations in this gene have been associated with congenital myasthenic syndrome. Alternatively spliced transcript variants have been described.[provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
869 residues, UniProt reviewed canonical sequence.
>O15146|MUSK
1 MRELVNIPLV HILTLVAFSG TEKLPKAPVI TTPLETVDAL VEEVATFMCA VESYPQPEIS
61 WTRNKILIKL FDTRYSIREN GQLLTILSVE DSDDGIYCCT ANNGVGGAVE SCGALQVKMK
121 PKITRPPINV KIIEGLKAVL PCTTMGNPKP SVSWIKGDSP LRENSRIAVL ESGSLRIHNV
181 QKEDAGQYRC VAKNSLGTAY SKVVKLEVEV FARILRAPES HNVTFGSFVT LHCTATGIPV
241 PTITWIENGN AVSSGSIQES VKDRVIDSRL QLFITKPGLY TCIATNKHGE KFSTAKAAAT
301 ISIAEWSKPQ KDNKGYCAQY RGEVCNAVLA KDALVFLNTS YADPEEAQEL LVHTAWNELK
361 VVSPVCRPAA EALLCNHIFQ ECSPGVVPTP IPICREYCLA VKELFCAKEW LVMEEKTHRG
421 LYRSEMHLLS VPECSKLPSM HWDPTACARL PHLDYNKENL KTFPPMTSSK PSVDIPNLPS
481 SSSSSFSVSP TYSMTVIISI MSSFAIFVLL TITTLYCCRR RKQWKNKKRE SAAVTLTTLP
541 SELLLDRLHP NPMYQRMPLL LNPKLLSLEY PRNNIEYVRD IGEGAFGRVF QARAPGLLPY
601 EPFTMVAVKM LKEEASADMQ ADFQREAALM AEFDNPNIVK LLGVCAVGKP MCLLFEYMAY
661 GDLNEFLRSM SPHTVCSLSH SDLSMRAQVS SPGPPPLSCA EQLCIARQVA AGMAYLSERK
721 FVHRDLATRN CLVGENMVVK IADFGLSRNI YSADYYKANE NDAIPIRWMP PESIFYNRYT
781 TESDVWAYGV VLWEIFSYGL QPYYGMAHEE VIYYVRDGNI LSCPENCPVE LYNLMRLCWS
841 KLPADRPSFT SIHRILERMC ERAEGTVSVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against MUSK can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.33
- Highest tissue expression
- 3.8 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 3.8 nTPM
- small intestine: 2.7 nTPM
- rectum: 2.3 nTPM
- tongue: 1.9 nTPM
- tonsil: 1.8 nTPM
- colon: 1.7 nTPM
Single-cell type
- myosatellite cells: 618 nCPM
- epicardial cells: 430 nCPM
- thymic myoid cells: 386 nCPM
- ependymal cells: 194 nCPM
- peritubular myoid cells: 183 nCPM
- fibro-adipogenic progenitors: 160 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 15 nTPM
- white matter: 12 nTPM
- medulla oblongata: 7.8 nTPM
- basal ganglia: 7.6 nTPM
- spinal cord: 7.4 nTPM
- thalamus: 5.7 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MUSK.
Disease | AllUniProt
Conditions MUSK is implicated in, by any mechanism.
- Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency (CMS9) MIM:616325
- Fetal akinesia deformation sequence 1 (FADS1) MIM:208150
Disease | GeneticClinVar
75 pathogenic / likely-pathogenic of 894 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Congenital myasthenic syndrome 9
- Fetal akinesia deformation sequence 1
- Bilateral ptosis
- Respiratory insufficiency
- Stridor
Disease | AutoantibodyPubMed
Conditions in which antibodies against MUSK are reported. Each links to that disease's full target list.
Showing 5 of 16 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for MUSK from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
297 publications
- Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
2023 · Lancet Neurol · RCR 31.1 · 221 citations - Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
2001 · Nat Med · RCR 19.9 · 851 citations - Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.
2024 · Nat Rev Neurol · RCR 16.4 · 95 citations - Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells.
2023 · Nat Biotechnol · RCR 15.8 · 160 citations - Myasthenia gravis: the future is here.
2024 · J Clin Invest · RCR 15.5 · 79 citations
Show 20 more of 297 total
- Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
2003 · Brain · RCR 11.7 · 466 citations - Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
2025 · Lancet Neurol · RCR 10.4 · 28 citations - Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
2020 · Front Immunol · RCR 10.3 · 186 citations - IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
2008 · Brain · RCR 9.7 · 353 citations - Clinical aspects of MuSK antibody positive seronegative MG.
2003 · Neurology · RCR 8.6 · 309 citations - Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.
2011 · Muscle Nerve · RCR 8.6 · 254 citations - A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
2014 · J Autoimmun · RCR 8.6 · 232 citations - B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.
2024 · EMBO Mol Med · RCR 8.4 · 60 citations - Long-lasting treatment effect of rituximab in MuSK myasthenia.
2012 · Neurology · RCR 8.1 · 255 citations - Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
2012 · Arch Neurol · RCR 7.4 · 234 citations - MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.
2013 · Proc Natl Acad Sci U S A · RCR 7 · 214 citations - Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
2020 · Front Immunol · RCR 6.3 · 114 citations - Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.
2024 · Eur J Neurol · RCR 5.7 · 16 citations - Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
2016 · F1000Res · RCR 5.7 · 142 citations - Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.
2020 · Front Neurol · RCR 5 · 85 citations - Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
2013 · J Clin Invest · RCR 4.9 · 157 citations - A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study.
2023 · Lancet Reg Health West Pac · RCR 4.6 · 28 citations - Rituximab in AChR subtype of myasthenia gravis: systematic review.
2020 · J Neurol Neurosurg Psychiatry · RCR 4.6 · 69 citations - Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
2022 · J Neurol Neurosurg Psychiatry · RCR 4.3 · 43 citations - Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis.
2023 · Neurol Neuroimmunol Neuroinflamm · RCR 4.3 · 39 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0
- gnomAD missense Z
- 1.09
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell differentiation
- cell surface receptor protein tyrosine kinase signaling pathway
- memory
- neuromuscular junction development
- positive regulation of gene expression
- positive regulation of protein phosphorylation
- regulation of synaptic assembly at neuromuscular junction
- skeletal muscle acetylcholine-gated channel clustering
- positive regulation of protein geranylgeranylation
Molecular functions
- ATP binding
- metal ion binding
- protein tyrosine kinase activity
- transmembrane receptor protein tyrosine kinase activity
- Wnt-protein binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Protein kinase domain
- Serine-threonine/tyrosine-protein kinase, catalytic domain
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Immunoglobulin-like domain
- Tyrosine-protein kinase, active site
- Protein kinase-like domain superfamily
- Immunoglobulin I-set
- Immunoglobulin-like fold
- Protein kinase, ATP binding site
- Frizzled domain
- Tyrosine-protein kinase, catalytic domain
- Immunoglobulin-like domain superfamily
- Frizzled cysteine-rich domain superfamily
- Receptor Tyrosine Kinase
- Fz domain
- Immunoglobulin I-set domain
- Protein tyrosine and serine/threonine kinase
- Immunoglobulin domain
KeywordsUniProt
- ATP-binding
- Cell membrane
- Congenital myasthenic syndrome
- Developmental protein
- Differentiation
- Disulfide bond
- Glycoprotein
- Immunoglobulin domain
- Kinase
- Magnesium
- Membrane
- Metal-binding
- Muscle protein
- Nucleotide-binding
- Phosphoprotein
- Postsynaptic cell membrane
- Receptor
- Repeat
- Signal
- Synapse
- Transferase
- Transmembrane
- Transmembrane helix
- Tyrosine-protein kinase
- Ubl conjugation
InteractionsUniProt · HPA
Protein binding partners of MUSK in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MUSK as an antibody target. Whether an autoantibody or antibody against MUSK could matter depends on whether native MUSK is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MUSK is annotated at the cell surface, where native MUSK is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label MUSK as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...